lyndacarol wrote: ↑
Mon Jan 13, 2020 12:18 pm
Please confirm that the URL is correct and give us the title to the paper where these remarks were found.
Sorry. I thought it was working worldwide. Maybe the URL works only from my university. Here are the paper data and the abstract:
Fereshte Ashtari, Reyhanehsadat Madanian, Vahid Shaygannejad, Sayyed Hamid Zarkesh, Keyvan Ghadimi
Serum levels of IL-6 and IL-17 in multiple sclerosis, neuromyelitis optica patients and healthy subjects
Int J Physiol Pathophysiol Pharmacol 2019;11(6):267-273
Studies reported that evaluating the interleukin serum level of MS and NMO patients is help-ful for differentiating these two diseases from each other. This study aimed to compare the level of IL-6 and IL-17 in MS and NMO patients and healthy subjects.
This study is a case control study that evaluated the serum level of IL-6 and IL-17 in MS and NMO patients in comparison to controls in patients who referred to Kashani hospital clinics. The level of serum IL-6 and IL-17 were measured by ELISA test in all patients. Participants were divided in to three groups include MS patients, NMO patients and controls and the level of IL-6 and IL-17 were compared in this three groups.
Mean of serum level of IL-6 in the NMO group was significantly lower than MS and healthy subject (P=0.02 for NMO and MS, P=0.001 for NMO and healthy subjects) but there was no significant difference between MS and healthy subjects (P=0.09). The mean of serum level of IL-17 in the MS and NMO were significantly higher than healthy subjects (P<0.001 for both). Also the mean of serum level of IL-17 in the MS was significantly higher than NMO (P=0.01). A positive significant correlation between age and serum level of IL-6 in all subjects (r=0.23, P=0.01). There was a positive significant correlation between age and serum level of IL-17 in MS and NMO patients (r=0.28, P=0.012).
Using IL-17 and IL-6 were inflammatory markers to diagnosis of NMO, MS and healthy subjects.